2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Coronary Heart Disease (CHD): new trials by email Literature Review of Coronary Heart Disease (CHD) trials Research Report on Coronary Heart Disease (CHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Evolocumab, Placebo - Coronary Heart Disease (CHD) | Phase 3 | Completed | Amgen | 12301 | 2019-06-11 | 2026-06-25 |
| Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) anacetrapib, Comparator: placebo - Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1623 | 2008-03-24 | 2017-12-11 |
Coronary Disease (2) · Multiple Endocrine Neoplasia Type 1 (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Myocardial Ischemia (2) · Vascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Multiple Primary (1) · Neoplastic Syndromes, Hereditary (1)
anacetrapib (1) · evolocumab (1)
Amgen (1) · Merck Sharp & Dohme LLC (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1)
PMID 19781408, PMID 21082868, PMID 24737712, PMID 25670362, PMID 41211925, PMID 41903215, PMID 42153665, PMID 42183757, PMID 42663360, PMID 42670293
2018 (1), 2023 (1)